|
|
|
| home > news > detailed info |
|
|
 INDUSTRY NEWS AND PRESS RELEASES |
Myonex Opens New Global Headquarters |
 |
|
Ribbon-cutting celebrates new 65,000-sq.-ft. office and GMP warehouse in Horsham, Pa.
Horsham, PA, September 23, 2021 – Myonex, a leading global clinical trial supply company, marked the opening of its new global headquarters and US operational facility with a ribbon-cutting ceremony on the company’s 14-acre campus.
“Let’s take a moment to remember the deeper reason why we’re here,” James Lovett, Chief Executive Officer at Myonex, said at the Sept. 21 event, noting that people die of diseases for which “the cures are not ready yet. For every patient, we are in a race against time to discover the right cure. At Myonex, our purpose—and this building’s purpose—is to help win this race more often.”
Acknowledging the critical importance of clinical trials, which take an average of six years and fall behind schedule 85 percent of the time, Lovett said, “At Myonex, our mission is to make clinical trial supply faster and less expensive” with services like packaging and distribution that can respond quickly to protocol changes; a new CTRx prescription service that can speed study start-up and eliminate wasted doses; end-to-end supply chain management for key equipment and supplies; and unique global drug sourcing capabilities that can potentially save millions of dollars.
“When we keep the focus on our customers, the patients and each other, there is nothing we can’t accomplish,” said Michael Cohen, Myonex’s Executive Chairman.
The 65,000-square-foot facility features a 45,000-sq.-ft. warehouse and distribution center with staging, shipping and receiving areas; rack storage in ambient temperatures and 2–8-degree Celsius cold box; -20-degree C and -80-degree C freezer storage; and secondary labeling rooms, all designed to current good manufacturing practices (GMP) guidelines.
The building’s 20,000 square feet of office space is designed to provide a great working environment, with adjustable ergonomic desks, showers, a comfort room and other amenities for employees. It incorporates low-emitting materials and LED lighting with motion sensors to reduce the environmental footprint.
The ribbon-cutting was held in person on site and live-streamed for the company’s customers and its employees in the United Kingdom and Germany. It included a video tour of the new facility, showing office spaces as well as operational areas and features such as the label control room, the secure cage in the cold-storage room, quarantine and returns cages and walk-in freezer.
The new facility was necessary to support the company’s growth, and the site can accommodate further expansion. |
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Moderna Expands Its mRNA Pipeline with Three New Development Programs
CAMBRIDGE, MA / ACCESSWIRE / February 18, 2022 / Moderna, Inc.
(NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA)
therapeutics and vaccines, today announced that it is expanding its mRNA
pipeline with three new development programs. This announcement
reflects the Company's commitment to expanding its portfolio building on
Moderna's experience with Spikevax®, its COVID-19 vaccine. The
development programs announced today are mRNA vaccine candidates against
herpes simplex virus (HSV), varicella-zoster virus (VSV) to reduce the
rate of shingles and a new checkpoint cancer vaccine. HSV and VZV are
latent viruses that remain in the body for life after infection and can
lead to life-long medical conditions. Moderna now has five vaccine
candidates against latent viruses in development, including against
cytomegalovirus (CMV), Epstein-Barr virus (EBV), Human immunodeficiency
virus (HIV), HSV and VZV.
More info >> |
|
 |
White Papers |
 |
|
|
